poisar

Stocks · News reference

Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200

Fiscal.ai

Polaryx Therapeutics has officially activated the first clinical trial site for its SOTERIA Phase 2 basket trial, which is evaluating the company's lead candidate, PLX-200.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading